跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
cell-mediated immunotherapy
首页
药物
cell-mediated immunotherapy
cell-mediated immunotherapy
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
US 9657105 B2
申请人: FORMAN STEPHEN
优先权: 2013
CN
EP
US
WO
11 件公开
ARTIFICIAL ANTIGEN PRESENTING CELLS COMPRISING PROTEIN L FOR EXPANDING IMMUNE CELLS FOR IMMUNOTHERAPY
EP 3801570 A4
申请人: H LEE MOFFITT CANCER CENTER & RES INSTITUTE INC
优先权: 2018
EP
US
WO
5 件公开
Method and compositions for cellular immunotherapy
US 10865242 B2
申请人: SEATTLE CHILDRENS HOSPITAL
优先权: 2014
CN
US
5 件公开
COMPOSITION FOR IMMUNOTHERAPY AND PREPARATION METHOD THEREOF
EP 3793572 A4
申请人: BADEN R&D LABORATORIES GMBH
优先权: 2019
CN
EP
US
WO
4 件公开
IMMUNOTHERAPY COMPOUNDS AND METHODS
EP 4031565 A4
申请人: UNIV MINNESOTA
优先权: 2019
CN
EP
US
WO
4 件公开
HYPERACTIVE DENDRITIC CELLS ENABLE DURABLE ADOPTIVE CELL TRANSFER-BASED ANTI-TUMOR IMMUNITY
EP 4061423 A4
申请人: CHILDRENS MEDICAL CENTER
优先权: 2019
CN
EP
US
WO
4 件公开
STIMULI THAT HYPERACTIVATE RESIDENT DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY
EP 4061409 A4
申请人: CHILDRENS MEDICAL CENTER
优先权: 2019
CN
EP
US
WO
4 件公开
DICKKOPF2 (DKK2) INHIBITION SUPPRESSES TUMOR FORMATION
EP 3978524 A1
申请人: UNIV YALE
优先权: 2014
CN
EP
US
4 件公开
SEQUENTIAL HETEROLOGOUS BOOST ONCOLYTIC VIRAL IMMUNOTHERAPY
EP 3941514 A4
申请人: TURNSTONE BIOLOGICS INC
优先权: 2019
EP
US
WO
4 件公开
Methods and compositions for liquidation of tumors
US 2011142887 A1
申请人: IMMUNOVATIVE THERAPIES LTD
优先权: 2009
CN
US
4 件公开
第 1 / 10 页
上一页
下一页
药物
反馈